Supuran and colleagues found that selective CA9 inhibitors inhibited cell migration and spreading of breast cancer cells in the absence of oxygen, suggesting that CA9 is a pivotal target for antitumor therapy in patients with breast carcinoma [25,51]. The gene discussed is CA9; the disease is breast cancer.